# US 2026/0193180 A1 · Autophagy inducing compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0193180 A1
- Document ID: US20260193180A1
- Status: Published application
- Kind: A1
- Application number: 19/129,855
- Filed: 2023-11-14
- Published: 2026-07-09
- Earliest claimed: 2022-11-15
- Applicants: Samsara Therapeutics Inc.
- Inventors: Peter Hamley; Warren Galloway; Ben Atkinson
- Web page: https://patentgrep.com/patent/US20260193180A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/402: 1-aryl substituted, e.g. piretanide
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/58: attached in position 4
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 265/30: not condensed with other rings
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof, which are suitable for inducing and/or stimulating the process of autophagy, as well as compounds of formula (I) for use in medicine and the treatment of autophagy related diseases or disorders.

## Claims

### Claim 1

A compound according to formula (I)
or a salt, stereoisomer, tautomer or N-oxide thereof,
wherein
X is CH2, CHR4, NRN or O;
R1 is H, CN, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, or —O—C1-C4-alkylene-ORc, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R2 is H, CN, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, or —O—C1-C4-alkylene-ORc, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R3 is H, CN, halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, or —O—C1-C4-alkylene-ORc, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX; or
R1 and R2 together with the atoms to which they are attached form a 5- or 6-membered partially unsaturated heterocyclyl, wherein the aforementioned heterocyclic ring comprises one or more, same or different heteroatoms selected from O, N and S, wherein said N- and/or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R4 is H, C1-C4-alkyl, or —(CH2)p—NRaRb;
wherein
RN is H, or C1-C4-alkyl;
RX is C1-C4-alkyl, C1-C4-haloalkyl, NRaRb, or two RX form cyclopropyl;
Ra, Rb are independently of each other selected from H, and C1-C4-alkyl;
Rc is H, or C1-C4-alkyl;
m is 1, 2, or 3;
n is 0, 1, or 2;
p is 0, 1, 2, or 3.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is not

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
R1 is C1-C4-alkoxy, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R2 is halogen;
R3 is H or halogen; and
R4 is —(CH2)p—NRaRb.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein
R1 is C2-C4-alkoxy, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R2 is Cl;
R3 is H or Cl; and
R4 is —(CH2)p—NRaRb.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound according to formula (I) is a compound according to the following formula
wherein
R1 is C2-C4-alkoxy, wherein each substitutable carbon atom in the aforementioned groups is independently unsubstituted or substituted with one or more, same or different substituents RX;
R2 is Cl;
R3 is H or Cl; and
R4 is —(CH2)p—NRaRb.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein
X is CH2, or CHR4.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein
m is 1;
n is 0, 1 or 2, preferably 1 or 2; and
p is 0 or 1, preferably 1.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein the compound of formula (I) is present in the form of a salt, preferably in the form of a hydrochloride salt.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein the compound of formula (I) is selected from the group consisting of (S)-1-(2-ethoxy-5-(trifluoromethyl)benzyl)-3-methylpiperazine hydrochloride, (S)-(1-(2-ethoxy-5-(trifluoromethyl) benzyl) pyrrolidin-3-yl) methanamine hydrochloride, (S)-(1-(5-chloro-2-propoxybenzyl) pyrrolidin-3-yl) methanamine Hydrochloride, (S)-(1-(4,5-dichloro-2-ethoxybenzyl)pyrrolidin-3-yl)methanamine hydrochloride, (S)-(1-(4,5-dichloro-2-(cyclopropylmethoxy)benzyl)pyrrolidin-3-yl)methanamine hydrochloride, (S)-(1-(5-chloro-2-ethoxybenzyl)piperidin-3-yl)methanamine hydrochloride, (S)-(1-(5-chloro-2-(cyclopropylmethoxy)benzyl)piperidin-3-yl)methanamine hydrochloride, (S)-1-(5-chloro-2-ethoxybenzyl)-3-methylpiperazine hydrochloride, 1-(5-chloro-2-ethoxybenzyl)-4-ethylpiperazine, 1-(5-chloro-2-ethoxybenzyl)-N,N-dimethylpiperidin-4-amine, (S)-(1-(5-chloro-2-ethoxybenzyl)pyrrolidin-3-yl)methanamine hydrochloride, (S)-(1-(5-chloro-2-ethoxybenzyl)pyrrolidin-2-yl)methanamine Hydrochloride, (R)-(1-(5-chloro-2-ethoxybenzyl)pyrrolidin-2-yl)methanamine hydrochloride, (R)-1-(5-chloro-2-ethoxybenzyl)piperidin-3-amine hydrochloride, (S)-1-(5-chloro-2-ethoxybenzyl)piperidin-3-amine hydrochloride, (1-(5-chloro-2-ethoxybenzyl)azetidin-3-yl)methanamine Hydrochloride, and 1-(5-chloro-2-ethoxybenzyl)-4-isopropylpiperazine.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein the compound of formula (I) is selected from the group consisting of
(S)-(1-(3,5-dichloro-4-ethoxybenzyl)pyrrolidin-3-yl)methanamine hydrochloride, 1-[2-(3-chloro-4-ethoxyphenyl)ethyl]-4-piperidylamine hydrochloride,
(S)-1-{2-[3,5-dichloro-4-(2-methoxyethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
(R)-1-{[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]methyl}-3-pyrrolidinylamine hydrochloride,
(S)-1-{2-[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride, 1-[(3-chloro-4-ethoxyphenyl)methyl]-4-piperidylamine hydrochloride,
(R)-1-{2-[3,5-dichloro-4-(2-methoxyethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
(S)-1-{[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]methyl}-3-pyrrolidinylamine hydrochloride,
(R)-1-{2-[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
(S)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine formate,
(S)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
(R)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine formate,
(R)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
1-{[3-chloro-4-(cyclopropylmethoxy)phenyl]methyl}-4-piperidylamine hydrochloride,
5-{[(R)-3-(Aminomethyl)-1-pyrrolidinyl]methyl}-3-chloro-2-ethoxybenzonitrile hydrochloride,
3-{2-[(S)-3-Amino-1-piperidyl]ethyl}-4-ethoxybenzonitrile hydrochloride,
3-{2-[(R)-3-Amino-1-piperidyl]ethyl}-4-ethoxybenzonitrile hydrochloride,
5-{2-[(S)-3-amino-1-pyrrolidinyl]ethyl}-2-ethoxybenzonitrile hydrochloride,
3-{2-[(S)-3-Amino-1-pyrrolidinyl]ethyl}-4-ethoxybenzonitrile hydrochloride,
3-{2-[(R)-3-amino-1-pyrrolidinyl]ethyl}-4-ethoxybenzonitrile hydrochloride,
(R)-1-[2-(4-ethoxy-3-fluorophenyl)ethyl]-3-pyrrolidinylamine hydrochloride,
(R)-1-{2-[3-chloro-4-(2-methoxyethoxy)phenyl]ethyl}-3-piperidylamine hydrochloride,
1-[(3,5-Dichloro-4-ethoxyphenyl)methyl]-4-piperidylamine hydrochloride,
1-{2-[3,5-Dichloro-4-(cyclopropylmethoxy)phenyl]ethyl}-4-piperidylamine hydrochloride,
(S)-1-[(3-chloro-4-ethoxyphenyl)methyl]-3-piperidylamine hydrochloride,
(R)-1-[(3-chloro-4-ethoxyphenyl)methyl]-3-piperidylamine hydrochloride,
1-{[3,5-dichloro-4-(2-methoxyethoxy)phenyl]methyl}-4-piperidylamine hydrochloride,
1-{[3-chloro-4-(2-methoxyethoxy)phenyl]methyl}-4-piperidylamine hydrochloride,
(S)-1-{[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]methyl}-3-piperidylamine hydrochloride,
(R)-1-{[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]methyl}-3-piperidylamine hydrochloride,
1-{[3,5-dichloro-4-(cyclopropylmethoxy)phenyl]methyl}-4-piperidylamine hydrochloride,
(R)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-pyrrolidinylamine hydrochloride,
(S)-1-{2-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-3-pyrrolidinylamine hydrochloride,
({(S)-1-[(3-chloro-5-ethoxyphenyl)methyl]-3-pyrrolidinyl}methyl)amine hydrochloride, and
({1-[(5-chloro-2-ethoxyphenyl)methyl]-3-azetidinyl}methyl)amine hydrochloride.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 and optionally a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 12 (depends on 1)

A method for stimulating autophagy, comprising contacting cells with a compound according to claim 1 or a pharmaceutical composition comprising the compound to stimulate autophagy in the cells.

### Claim 13 (depends on 1)

A method for treating an autophagy-related disease or condition, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising the compound.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said autophagy-related disease or condition is selected from the group consisting of neurodegenerative diseases, Huntington's disease, Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, epilepsy, cancer, liver diseases (e.g. nonalcoholic fatty liver disease (NAFLD)), al antitrypsin deficiency, Charcot Marie Tooth syndrome, Rett Syndrome, Sickle Cell disease, Wilson Disease, amyloidosis, Gaucher's diseases, lysosomal and glycogen storage disorders (e.g., Glycogen Storage Disease type 1A (GSD1A)), cystic fibrosis; viral infection and diseases human cytomegalovirus (HCMV) infection, hepatitis B, human immunodeficiency virus infection, Zika virus infection, coronavirus infection, HCoV-229E, HCoV-NL63, betacoronavirus infection, such as HCoV-OC43, SARS-CoV-1, HCoV-HKU1, MERS-CoV or SARS-CoV-2, bacterial infections, metabolic disorders, diabetes, fibrosis, silicosis, diabetic retinopathy, glaucoma, cataracts, age-related macular degeneration, glomerulonephritis, glomerulosclerosis, wound healing disorders, Niemann-Pick type C (NPC) disease, fibrinogen storage disease (FSB), inclusion body disease (IBD), muscular dystrophy, Duchenne muscular dystrophy, Limb-girdle muscular dystrophy, myopathy, myofibrillar myopathy, hereditary myopathy, diabetic cardiomyopathy, anti-inflammatory disorders, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, irritable bowel syndrome, Crohn's disease, vascular disorders, stroke, coronary artery diseases, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis, Behcet's syndrome, giant cell arteritis, polymyalgia rheumatic, Wegener's granulomatosis, Churg-Strauss syndrome, vasculitis, Henoch-Schonlein pruprua, Kawasaki disease, viral infection or replication, pox virus infection, herpes virus infection, asthma, allergic rhinitis, COPD, osteoporosis, organ transplant rejection, psoriasis, hypertrophic scarring (keloid formation), adhesion formations following general or gynecological surgery, lung fibrosis, liver fibrosis, kidney fibrosis, disorders caused by intracellular parasites, malaria, tuberculosis, neuropathic pain, post-operative phantom limb pain or postherpetic neuralgia, allergies, amyotrophic lateral sclerosis (ALS), antigen induced recall response, immune response suppression, muscle degeneration and atrophy, frailty in aging, spinal cord injury, and diseases and conditions involving misfolded and/or nonfolded proteins.

### Claim 15 (depends on 13)

The method of claim 13, further comprising administering to the subject at least one additional pharmaceutically active substance for said autophagy-related disease or condition.

### Claim 16 (depends on 12)

The method of claim 12, wherein the method is an in-vitro assay.
